Clinical Trials Logo

Old Age clinical trials

View clinical trials related to Old Age.

Filter by:

NCT ID: NCT06296719 Not yet recruiting - Family Members Clinical Trials

The Chit-Chat Educational Intervention to Promote Advance Care Planning in the Community

Start date: April 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to estimate the effect size of the Chit-Chat intervention on ACP engagement among family members of older adults with multi-morbidity.

NCT ID: NCT06252025 Active, not recruiting - Clinical trials for Emotional Regulation

Immersive VR Reminiscence System for Facilitating Memory Retrieval Among Nursing Home Older Adults

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

A VR game "Memo-gration" was designed to assist elderly people in reminiscence therapy. The ultimate scene design was crafted in a vintage Chinese aesthetic reminiscent of the previous century.

NCT ID: NCT06085248 Recruiting - Stroke Clinical Trials

Responders to Rhythmic Auditory Stimulation in Individuals Post-Stroke and Older Adults

Start date: September 18, 2023
Phase: Phase 1
Study type: Interventional

Stroke is among the leading causes of long-term disability worldwide. Post-stroke neuromotor impairments are heterogeneous, yet often result in reduced walking ability characterized by slow, asymmetric, and unstable gait patterns. Rhythmic Auditory Stimulation (RAS) is an emerging rehabilitation approach that leverages auditory-motor synchronization to retrain neuromotor control of walking. Indeed, walking with RAS can enhance walking rhythmicity, gait quality, and speed. RAS is a potentially valuable tool for walking rehabilitation after stroke; however, despite extensive research evidence on the overall benefits of RAS in people with chronic stroke, the notable variability in the walking characteristics of individual patients is likely to influence the effectiveness of RAS intervention, and thus requires study. Furthermore, beyond stroke-related factors, age-related changes may also affect how well individuals post-stroke respond to RAS. This study aims to recruit 24 individuals post-stroke and 20 older adults to evaluate the effects of stroke- and age-related neuromotor impairment on RAS intervention. Each study participant will complete two six-minute walk tests: one without RAS (baseline) and the other with RAS delivered using a metronome. The investigators hypothesize that post-stroke individuals will, on average, exhibit a positive response to RAS intervention (i.e., walk farther and with greater gait automaticity (i.e., reduced stride time variability), with the degree of response predicted by specific baseline characteristics. Furthermore, the investigators anticipate that these walking enhancements will be accompanied by improvements in gait biomechanics and a reduction in the metabolic cost of walking. The investigators hypothesize that older adults will exhibit similar, but attenuated, effects of RAS.

NCT ID: NCT05963399 Not yet recruiting - Old Age Clinical Trials

An Integrated Care Platform Based on the Monitoring of Older Individual Intrinsic Capacity for Inclusive Health (CAREUP)

CAREUP
Start date: April 30, 2024
Phase: N/A
Study type: Interventional

The objective of this study is to assess the usability and acceptance of the CAREUP solution in improving the quality of life at home of the older adults. The CAREUP solution is a platform that collects data from different tools such as tablets, smartwatches, ambient sensors, iHealth weight scale, and Digital Hand Dynamometer. .

NCT ID: NCT05950646 Recruiting - Dexmedetomidine Clinical Trials

Mini-dose Dexmedetomidine-Esketamine Infusion and Perioperative Sleep Quality

Start date: November 1, 2023
Phase: Phase 4
Study type: Interventional

Sleep disturbances are prevalent in older patients with osteoarthrosis or fracture who are scheduled for knee or hip replacement surgery. The occurrence of sleep disturbances is associated with worse outcomes including increased risk of delirium and cardiac events, and worsened functional recovery. Dexmedetomidine is a highly selective α2-adrenergic agonist with sedative, anxiolytic, and analgesic properties. It exerts sedative effects via activating the endogenous sleep pathways and produces a state like non-rapid eye movement sleep, which is different from opioid- and benzodiazepine-induced sedation. Esketamine is a N-methyl-D-aspartic acid receptor antagonist and has been used as an anesthetic and analgesic. Recent studies showed that low-dose esketamine has anti-depressive and sleep-promoting effects. The investigators suppose that mini-dose dexmedetomidine-esketamine combined infusion at night can improve perioperative sleep quality in patients scheduled for knee or hip replacement surgery.

NCT ID: NCT05346770 Enrolling by invitation - Old Age Clinical Trials

Pharmacist-led Interventions to Improve Medication Use

Start date: January 25, 2022
Phase:
Study type: Observational

The objective of this project is to stimulate identification and report of patient's medical story for whom their clinical conditions beneficiated from pharmacists' interventions based on a medication safety review. Cases will be systematically identified and reported in the scientific (peer review journals) and clinical communities in order to inform and provide better care.

NCT ID: NCT05246007 Not yet recruiting - Dexmedetomidine Clinical Trials

Nocturnal Low-dose Dexmedetomidine Infusion and Perioperative Sleep Quality

Start date: May 2022
Phase: N/A
Study type: Interventional

Sleep disturbances are prevalent in older patients with osteoarthrosis or fracture scheduled for knee or hip replacement surgery. The occurrence of sleep disturbances is associated with worse outcomes including increased risk of delirium and cardiac events, and worsened functional recovery. Dexmedetomidine is a highly selective α2-adrenergic agonist with sedative, anxiolytic, and analgesic properties. It exerts sedative effects via activating the endogenous sleep pathways and produces a state like non-rapid eye movement sleep, which is different from opioid- and benzodiazepine-induced sedation. Night-time infusion of low-dose dexmedetomidine may improve sleep quality. However, evidence in this aspect is limited.

NCT ID: NCT05200039 Completed - Prostate Cancer Clinical Trials

Health Status, Quality of Life and Function in Survivors After Radical Treatment for Prostate Cancer. Part IIB

OPSIIB
Start date: December 21, 2021
Phase:
Study type: Observational

The present study is the last part of a larger project investigating the health, quality of life and function of men having received radical treatment for prostate cancer in 2014-2018. In this study, physical function and level of physical activity will be tested and registered in a selection of older men who participated in the foregoing parts of the project. Comparisons will be made to similar data from a population-based cohort, matched on age and education.

NCT ID: NCT05037084 Active, not recruiting - Frailty Clinical Trials

Activity and Health in Nursing Homes

Start date: August 30, 2021
Phase:
Study type: Observational

There is expected to be an increased need for full time nursing homes as the increase in number of older adults increases and the rate of dementia diagnosis happens simultaneous with the decrees of healthcare personnel the years to come. A lift in knowledge is needed to provide a better and more efficient healthcare to be better equipped to meet this societal challenge. Physical activity and sleep are important indicators of health, but also on effect of treatment and care for this frail population. Comprehensive mapping of personnel time spent on different tasks and older adults' physical function throughout a week gives a unique opportunity to gain new knowledge about everyday life in nursing homes. The main aim of this project is to describe associations between physical behavior, sleep and symptoms in residents in nursing homes in Trondheim Municipality and combine these with personnel time spent on different working tasks.

NCT ID: NCT04953312 Not yet recruiting - Clinical trials for Myelodysplastic Syndromes

Calprotectin, a Biomarker of COVID-19 Severity (CALPRO)

CALPRO
Start date: January 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to provide new insights into the pathophysiology of emergency hematopoiesis detected in severe COVID-19 patients. The investigators aim to explore the ability of calprotectin to induce an immunosuppressive myeloid program at the hematopoietic stem and progenitor cell (HSPC) level, and to identify the receptor(s) involved in this effect. Since patients with a hematological malignancy demonstrate a very high propensity to develop a severe COVID-19, the investigators will explore how HSPCs collected from patients with a myeloid malignancy respond to calprotectin.